Introduction: pharmacogenomics 101 for PDE5 Inhibitors While sildenafil is widely effective for erectile dysfunction and pulmonary hypertension, its pharmacokinetic variability remains a clinical challenge. Standard […]
Sildenafil’s therapeutic applications now extend far beyond erectile dysfunction, including indications in pulmonary hypertension, HFpEF, and off-label cardiovascular use. Yet its metabolic vulnerability to CYP3A […]
Introduction: Why Formulation Still Matters Though sildenafil remains the leading oral treatment for erectile dysfunction, its conventional film-coated tablet (FCT) form has drawbacks: delayed onset, […]
Author: Sylvia (Xi) He – Medical / Scientific Editor & Writer Why “Cheap” Can Be Risky: How to Spot Illegitimate Pharmacies Searches for “buy Cialis […]
Introduction Premature ejaculation (PE) affects up to 30% of men worldwide and remains one of the most underreported and undertreated sexual health conditions. While pharmacologic […]
Introduction Sildenafil, a potent PDE5 inhibitor, remains widely used not only for erectile dysfunction but also for pulmonary hypertension and investigational cardiac indications. Yet visual […]
Mechanisms: Hormone Blocker vs Follicle Energiser Finasteride is a 5-α-reductase inhibitor: one pill a day lowers scalp dihydrotestosterone (DHT) by ≈ 70 %, slowing the […]
Why Another Update? Once confined to glycemic control in type 2 diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors have firmly entrenched themselves as foundational agents in […]
Since its approval nearly three decades ago, losartan has become a mainstay of cardiovascular and renal therapy. As the first angiotensin II receptor blocker (ARB) […]
Mechanisms: Dual Enzyme Blocker vs Selective Blocker Finasteride inhibits only type II 5-α-reductase, the isoenzyme dominant in scalp follicles; dutasteride blocks both type I and […]